Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy (DMD) therapy, ...

(RTTNews) - Capricor Therapeutics, Inc. (CAPR), Tuesday announced a deal with Japan-based Nippon Shinyaku Co., Ltd., to commercialize and distribute deramiocel in Europe, which is used for the ...

Capricor Therapeutics Inc (NASDAQ:CAPR) entered into a binding term sheet with Nippon Shinyaku Co., Ltd., a Japanese ...

Capricor will receive an upfront payment of $20 million subject to execution of the definitive agreement, and there are potential additional development and sales-based milestone payments to Capricor ...

Capricor Therapeutics (CAPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Capricor Therapeutics has a 12-month low of $2.68 and a 12-month high of $7.28. The company has a market cap of $163.73 million, a price-to-earnings ratio of -5.89 and a beta of 3.92.

Capricor Therapeutics press release (NASDAQ:CAPR): Q2 GAAP EPS of -$0.35 beats by $0.01. Revenue of $3.97M (+1.3% Y/Y) beats by $0.31M. Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD ...

While the debate now is over how much the Fed will cut at its September meeting, it's increasingly clear that interest rates are headed lower.

US biotech Capricor Therapeutics has entered into a binding term sheet with Japanese drugmaker Nippon Shinyaku for the ...

The average one-year price target for Capricor Therapeutics (NASDAQ:CAPR) has been revised to 26.52 / share. This is an increase of 16.42% from the prior estimate of 22.78 dated October 4 ...

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...